| 前收市價 | 381.20 |
| 開市 | 381.20 |
| 買盤 | 0.00 |
| 賣出價 | 0.00 |
| 拍板 | 340.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 381.20 - 381.20 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2 |
ZacksRegeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
BenzingaWhat's Going On With Regeneron Pharmaceuticals Stock On Friday?
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional approval of odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Relapsed/refractory (R/R) follicular lymphoma (FL) refers to cases where FL comes back after initial treatment (relapsed) or
InvestorPlaceWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
Investors looking for long-term returns should consider investing in strong buy Cathie Wood stocks this month. The ARK Invest Chief Executive Officer (CEO) gained a massive following in 2020 after all six of her exchange traded funds (ETFs) saw returns above 100%. Since then, Wood has been hailed as a star stock picker for her well-justified high risk/high reward plays. Four years later, Wood is still going strong and appealing to investors with her belief in disruptive technologies and contrari
